Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic kidney disease
Biotech
AstraZeneca's failed cancer drug gets new life in CKD trial
A decade after AstraZeneca gave up on using zibotentan to treat prostate cancer, the endothelin receptor antagonist has received a new lease on life.
James Waldron
Nov 3, 2023 11:30am
Novo Nordisk buys rival to Bayer's Kerendia in $1.3B deal
Oct 16, 2023 9:30am
Renalytix nabs FDA nod for AI-powered kidney disease test
Jul 6, 2023 12:47pm
Novartis inks $3.2B Chinook buyout to lift kidney disease plans
Jun 12, 2023 4:50am
Boehringer, Healthy.io partner on at-home kidney disease testing
May 11, 2023 12:52pm
Reata, Kyowa Kirin ax bardoxolone, ending 13-year saga
May 10, 2023 10:22am